Great to see you back on BIT threads TP (your posts inspired me...

Great to see you back on BIT threads TP (your posts inspired me to research BIT over 12 months ago).

I'm hoping that the next trial is a HIV/HCV co-infected patient one. My thinking is that the novel ion-channel technology held by BIT needs to be applied across a viral spread rather than focussing on HCV only. This publication (originally posted by Neo) also mentions applicability to SARS.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027660

Given drug resistance issues with the new generation drugs for HCV there will always be an opportunity to throw BIT225 into the mix for a shotgun approach to this disease.

Certainly value your input here

bluebush